132 related articles for article (PubMed ID: 29019023)
1. Challenges Associated with Estimating Utility in Wet Age-Related Macular Degeneration: A Novel Regression Analysis to Capture the Bilateral Nature of the Disease.
Hodgson R; Reason T; Trueman D; Wickstead R; Kusel J; Jasilek A; Claxton L; Taylor M; Pulikottil-Jacob R
Adv Ther; 2017 Oct; 34(10):2360-2370. PubMed ID: 29019023
[TBL] [Abstract][Full Text] [Related]
2. Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom.
Claxton L; Hodgson R; Taylor M; Malcolm B; Pulikottil Jacob R
Pharmacoeconomics; 2017 Feb; 35(2):237-248. PubMed ID: 27787744
[TBL] [Abstract][Full Text] [Related]
3. SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration.
Visser MS; Amarakoon S; Missotten T; Timman R; Busschbach JJ
PLoS One; 2017; 12(2):e0169816. PubMed ID: 28225799
[TBL] [Abstract][Full Text] [Related]
4. A systematic literature review of utility weights in wet age-related macular degeneration.
Pearson I; Rycroft C; Irving A; Ainsworth C; Wittrup-Jensen K
J Med Econ; 2013 Nov; 16(11):1307-16. PubMed ID: 24004384
[TBL] [Abstract][Full Text] [Related]
5. Patient and public preferences for health states associated with AMD.
Butt T; Dunbar HM; Morris S; Orr S; Rubin GS
Optom Vis Sci; 2013 Aug; 90(8):855-60. PubMed ID: 23811607
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Relationship Between Visual Acuity and Utilities in Patients With Diabetic Macular Edema Enrolled in Intravitreal Aflibercept Studies.
Brazier J; Muston D; Konwea H; Power GS; Barzey V; Lloyd A; Sowade O; Vitti B; Gerlinger C; Roberts J
Invest Ophthalmol Vis Sci; 2017 Sep; 58(11):4818-4825. PubMed ID: 28973328
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
Wolowacz SE; Roskell N; Kelly S; Maciver FM; Brand CS
Pharmacoeconomics; 2007; 25(10):863-79. PubMed ID: 17887807
[TBL] [Abstract][Full Text] [Related]
8. Validity of EuroQOL-5D, time trade-off, and standard gamble for age-related macular degeneration in the Singapore population.
Au Eong KG; Chan EW; Luo N; Wong SH; Tan NW; Lim TH; Wagle AM
Eye (Lond); 2012 Mar; 26(3):379-88. PubMed ID: 22222257
[TBL] [Abstract][Full Text] [Related]
9. Burden of Wet Age-Related Macular Degeneration and Its Economic Implications in Singapore in the Year 2030.
Saxena N; George PP; Hoon HB; Han LT; Onn YS
Ophthalmic Epidemiol; 2016 Aug; 23(4):232-7. PubMed ID: 27340738
[TBL] [Abstract][Full Text] [Related]
10. The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK.
Ghosh W; Wickstead R; Claxton L; Kusel J; Taylor M; Fleetwood K; Pulikottil-Jacob R
Adv Ther; 2016 Sep; 33(9):1660-76. PubMed ID: 27457470
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
Vottonen P; Kankaanpää E
Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported utilities in bilateral visual impairment from amblyopia and age-related macular degeneration.
van de Graaf ES; Despriet DDG; Klaver CCW; Simonsz HJ
BMC Ophthalmol; 2016 May; 16(1):56. PubMed ID: 27184381
[TBL] [Abstract][Full Text] [Related]
13. Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study.
Elshout M; Webers CA; van der Reis MI; de Jong-Hesse Y; Schouten JS
BMC Ophthalmol; 2017 Jul; 17(1):120. PubMed ID: 28693519
[TBL] [Abstract][Full Text] [Related]
14. The impact of age-related macular degeneration on health status utility values.
Espallargues M; Czoski-Murray CJ; Bansback NJ; Carlton J; Lewis GM; Hughes LA; Brand CS; Brazier JE
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4016-23. PubMed ID: 16249475
[TBL] [Abstract][Full Text] [Related]
15. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
16. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
[TBL] [Abstract][Full Text] [Related]
17. Quality of Life in Patients Suffering from Active Exudative Age-Related Macular Degeneration: The EQUADE Study.
Matamoros E; Maurel F; Léon N; Solomiac A; Bardoulat I; Joubert M; Hermans M; Moser E; Le Picard S; Souied EH; Leveziel N
Ophthalmologica; 2015; 234(3):151-9. PubMed ID: 26337381
[TBL] [Abstract][Full Text] [Related]
18. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
Fletcher EC; Lade RJ; Adewoyin T; Chong NV
Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Visual Function in Older Eyes in the Earliest Stages of Age-related Macular Degeneration to Those in Normal Macular Health.
Owsley C; Huisingh C; Clark ME; Jackson GR; McGwin G
Curr Eye Res; 2016; 41(2):266-72. PubMed ID: 25802989
[TBL] [Abstract][Full Text] [Related]
20. Health State Utility Values for Age-Related Macular Degeneration: Review and Advice.
Butt T; Tufail A; Rubin G
Appl Health Econ Health Policy; 2017 Feb; 15(1):23-32. PubMed ID: 27637920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
